Shares of Tocagen Inc (NASDAQ:TOCA) have earned an average rating of “Buy” from the eleven research firms that are covering the firm, Marketbeat.com reports. Three investment analysts have rated the stock with a hold recommendation and eight have issued a buy recommendation on the company. The average 12 month target price among brokerages that have updated their coverage on the stock in the last year is $16.00.
A number of research analysts recently issued reports on TOCA shares. HC Wainwright reissued a “buy” rating on shares of Tocagen in a research note on Friday, August 9th. Leerink Swann set a $5.00 price objective on shares of Tocagen and gave the company a “hold” rating in a research note on Wednesday, May 22nd. Chardan Capital reaffirmed a “buy” rating and set a $10.00 target price on shares of Tocagen in a research note on Wednesday, May 22nd. ValuEngine raised shares of Tocagen from a “hold” rating to a “buy” rating in a research note on Thursday, August 1st. Finally, Zacks Investment Research cut shares of Tocagen from a “buy” rating to a “hold” rating in a research note on Friday.
In related news, Director Faheem Hasnain bought 43,000 shares of the firm’s stock in a transaction on Thursday, May 30th. The shares were purchased at an average price of $4.66 per share, with a total value of $200,380.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In the last ninety days, insiders have acquired 53,000 shares of company stock worth $244,880. Insiders own 10.90% of the company’s stock.
Hedge funds and other institutional investors have recently bought and sold shares of the business. Rhumbline Advisers grew its stake in shares of Tocagen by 9.4% during the first quarter. Rhumbline Advisers now owns 25,491 shares of the company’s stock worth $277,000 after buying an additional 2,188 shares during the last quarter. Stifel Financial Corp grew its stake in shares of Tocagen by 34.0% in the fourth quarter. Stifel Financial Corp now owns 26,392 shares of the company’s stock worth $215,000 after purchasing an additional 6,698 shares during the last quarter. Squarepoint Ops LLC bought a new stake in shares of Tocagen in the fourth quarter worth $295,000. Bank of New York Mellon Corp grew its stake in shares of Tocagen by 7.7% in the fourth quarter. Bank of New York Mellon Corp now owns 56,938 shares of the company’s stock worth $468,000 after purchasing an additional 4,093 shares during the last quarter. Finally, Sphera Funds Management LTD. bought a new stake in shares of Tocagen in the first quarter worth $1,304,000. 35.06% of the stock is currently owned by hedge funds and other institutional investors.
NASDAQ:TOCA traded up $0.16 during mid-day trading on Friday, reaching $4.52. The stock had a trading volume of 263,000 shares, compared to its average volume of 174,154. The stock has a 50-day simple moving average of $5.51 and a two-hundred day simple moving average of $8.18. The stock has a market capitalization of $102.76 million, a PE ratio of -1.85 and a beta of 3.90. The company has a debt-to-equity ratio of 0.86, a current ratio of 4.21 and a quick ratio of 5.05. Tocagen has a 12 month low of $4.12 and a 12 month high of $15.80.
Tocagen (NASDAQ:TOCA) last announced its quarterly earnings data on Thursday, August 8th. The company reported ($0.72) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.76) by $0.04. The business had revenue of $0.01 million for the quarter, compared to analysts’ expectations of $0.50 million. Tocagen had a negative net margin of 300.42% and a negative return on equity of 115.81%. Equities analysts expect that Tocagen will post -2.67 EPS for the current year.
Tocagen Inc, a clinical-stage cancer-selective gene therapy company, focuses on developing and commercializing product candidates designed to activate a patient's immune system against their cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to deliver therapeutic genes into the DNA of cancer cells.
Featured Story: How interest rates affect municipal bond prices
Receive News & Ratings for Tocagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tocagen and related companies with MarketBeat.com's FREE daily email newsletter.